Published in FEMS Microbiol Lett on September 15, 1994
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev (1999) 5.51
Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother (1996) 3.03
Efflux-mediated antifungal drug resistance. Clin Microbiol Rev (2009) 2.44
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol (1998) 1.89
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Cholesterol and ergosterol superlattices in three-component liquid crystalline lipid bilayers as revealed by dehydroergosterol fluorescence. Biophys J (1997) 1.39
Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae. Antimicrob Agents Chemother (2003) 1.26
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 1.23
Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother (1995) 1.23
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. Genetics (1999) 1.15
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol (2012) 1.11
Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes. Antimicrob Agents Chemother (2004) 1.04
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother (2012) 1.02
Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2. Antimicrob Agents Chemother (2012) 0.91
A functional variomics tool for discovering drug-resistance genes and drug targets. Cell Rep (2013) 0.90
Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol (2015) 0.85
Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrob Agents Chemother (2005) 0.85
Overcoming antifungal resistance. Drug Discov Today Technol (2014) 0.85
Virulence-Associated Enzymes of Cryptococcus neoformans. Eukaryot Cell (2015) 0.84
The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother (2014) 0.84
Sterol and fatty acid composition of Candida lusitaniae clinical isolates. Antimicrob Agents Chemother (2002) 0.81
Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans. Antimicrob Agents Chemother (2002) 0.81
The molecular mechanism of a cis-regulatory adaptation in yeast. PLoS Genet (2013) 0.80
Cell Wall Changes in Amphotericin B-Resistant Strains from Candida tropicalis and Relationship with the Immune Responses Elicited by the Host. Antimicrob Agents Chemother (2016) 0.76
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis. Front Microbiol (2017) 0.75
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med (2012) 4.82
Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health (2003) 4.67
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother (1998) 3.09
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res (1996) 2.91
Effect of acid pH on the absorption spectra and photoreactions of bacteriorhodopsin. Biochemistry (1979) 2.89
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Ligand binding to heme proteins: connection between dynamics and function. Biochemistry (1991) 2.85
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72
Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun (1995) 2.66
Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699. Chem Biol (1998) 2.64
The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem (1997) 2.63
Thyroxine should be tried in clinically hypothyroid but biochemically euthyroid patients. BMJ (1997) 2.58
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Mental stress induces transient endothelial dysfunction in humans. Circulation (2000) 2.37
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation (2000) 2.27
Approaches to the construction of a medical informatics glossary and thesaurus. Med Inform (Lond) (1993) 2.18
Premedication of Children for Ambulatory General Anesthesia. J Am Dent Soc Anesthesiol (1958) 2.11
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Young people, HIV/AIDS/STIs and sexuality in South Africa: the gap between awareness and behaviour. Acta Paediatr (2004) 2.09
Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ (2003) 2.07
Pressure and breast thickness in mammography--an exploratory calibration study. Br J Radiol (2013) 2.06
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res (2001) 2.02
Ligand binding to heme proteins. VI. Interconversion of taxonomic substates in carbonmonoxymyoglobin. Biophys J (1996) 2.02
Micromethods for induction and assay of mouse mixed lymphocyte reactions and cytotoxicity. Eur J Immunol (1976) 1.90
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol (1996) 1.88
A method of preparing blood leucocytes for flow cytometry which prevents upregulation of leucocyte integrins. J Immunol Methods (1992) 1.86
Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85
RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology (1997) 1.83
Simulation of a knee joint replacement during a gait cycle using explicit finite element analysis. J Biomech (2002) 1.78
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Is housework good for health? Levels of physical activity and factors associated with activity in elderly women. Results from the British Women's Heart and Health Study. J Epidemiol Community Health (2002) 1.72
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Attenuated measles virus vaccine dosage study in Central Africa. J Trop Med Hyg (1970) 1.60
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Routine cleaning and the elimination of Campylobacter pylori from endoscopic biopsy forceps. J Hosp Infect (1989) 1.57
Determination of rate distributions from kinetic experiments. Biophys J (1992) 1.55
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Genetic structure of European sheep breeds. Heredity (Edinb) (2007) 1.52
The cytology of repair in experimental perforations of the tympanic membrane. Br J Surg (1966) 1.52
Influence of head constraint and muscle forces on the strain distribution within the intact femur. Med Eng Phys (2000) 1.50
Effect of early return to work after elective repair of inguinal hernia: Clinical and financial consequences at one year and three years. Lancet (1981) 1.50
Failure of blue-tinted lenses to change reading scores of dyslexic individuals. Optometry (2001) 1.49
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene (2012) 1.46
Hand grip dynamometry as a predictor of postoperative complications reappraisal using age standardized grip strengths. JPEN J Parenter Enteral Nutr (1989) 1.45
Prospective surveillance for perioperative venous thrombosis. Experience in 2643 patients. Arch Surg (1996) 1.45
Obstetric complications in patients with schizophrenia and their unaffected siblings. Eur Psychiatry (2005) 1.45
Neural correlates of theory-of-mind reasoning: an event-related potential study. Psychol Sci (2000) 1.42
Metabolic engineering of Geobacillus thermoglucosidasius for high yield ethanol production. Metab Eng (2009) 1.41
Beating the barriers: recruitment of people with intellectual disability to participate in research. J Intellect Disabil Res (2005) 1.41
Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett (1995) 1.41
Transfer RNA activities of Rous sarcoma and Rous associated viruses. Nat New Biol (1973) 1.40
Effects of dietary supplementation on work performance in Gambian laborers. Am J Clin Nutr (1991) 1.40
Monofunctional biosynthetic peptidoglycan transglycosylases. Mol Microbiol (1996) 1.39
Testing the internal consistency of the lottery equivalents method using health outcomes: a comment to Oliver. Health Econ (2005) 1.39
Pro-haemorrhagic effects of calcium antagonists: a comparison of isradipine and atenolol on ex vivo platelet function in hypertensive subjects. J Hum Hypertens (1997) 1.38
Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read (2003) 1.38
Thirty-five year review of a mercury monitoring service for Scottish dental practices. Br Dent J (2011) 1.38
The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14 alpha-demethylase of Candida albicans (other names are: lanosterol 14 alpha-demethylase, P-45014DM, and CYP51). J Biol Chem (1996) 1.38
Florida pediatric emergency nursing education project. J Emerg Nurs (1991) 1.37
Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation (2001) 1.35
Radiophosphorus and Radiostrontium in Mosquitoes. Preliminary Report. Science (1949) 1.33
Medical students' attitudes toward rural practice. J Med Educ (1973) 1.33
Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett (1999) 1.31
Physical, psychological and social well-being of women with breast cancer: the influence of disease phase. Psychooncology (2000) 1.30
Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS (1992) 1.29
Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther (1992) 1.29
The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun (1999) 1.29
Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents. J Biol Chem (1997) 1.28
Associations of components of adult height with coronary heart disease in postmenopausal women: the British women's heart and health study. Heart (2004) 1.28
Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nat Genet (2001) 1.28
Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting. Am J Physiol (1998) 1.27
Toxic megacolon with campylobacter colitis. Conn Med (1980) 1.26
Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol Lett (2000) 1.26
Analysis of the current status of public health practice in local health departments. Am J Prev Med (1996) 1.26
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer (2003) 1.25
Assessing literacy for patient teaching: perspectives of adults with low literacy skills. J Adv Nurs (1997) 1.24
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 1.23
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 1.22
Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab (2005) 1.21
Characterization of human IgG Fc receptors. J Immunol (1985) 1.21
Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med (2006) 1.21
The effect of sequential use of vacuum and forceps for assisted vaginal delivery on neonatal and maternal outcomes. Am J Obstet Gynecol (2001) 1.20
Verbal memory performance of patients with human immunodeficiency virus infection: evidence of subcortical dysfunction. The HNRC Group. J Clin Exp Neuropsychol (1994) 1.20